| References: |
LY2835219 is orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. CDK4/6 dual inhibitor LY2835219 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.For the detailed information of LY2835219, the solubility of LY2835219 in water, the solubility of LY2835219 in DMSO, the solubility of LY2835219 in PBS buffer, the animal experiment (test) of LY2835219, the cell expriment (test) of LY2835219, the in vivo, in vitro and clinical trial test of LY2835219, the EC50, IC50,and Affinity of LY2835219, Please contact DC Chemicals. |
